A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Inclusion Criteria:

For participants with relapsed or refractory multiple myeloma:

• Have a documented initial diagnosis of multiple myeloma according to InternationalMyeloma Working Group (IMWG) diagnostic criteria

• Part 1: Have relapsed or refractory disease, have been treated with a proteasomeinhibitor, immunomodulatory drug (IMiD) agent, and an anti-CD38-based therapy forthe treatment of multiple myeloma (MM),and should have been treated with at least 3prior lines of therapy, or are refractory to proteosome inhibitor, IMiD agent, andan anti-CD38-based therapy regardless of prior lines of therapy, Part 2: Haverelapsed or refractory disease, have been treated with a PI, IMiD and an anti-CD38based therapy

• Must have an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1

• Have measurable disease at screening as defined by at least 1 of the following: a)Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL);or b) Urine M-protein level >=200 milligrams (mg)/24 hours; or c) Light chainmultiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >=10 milligramsper deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio; d) Forparticipants without measurable disease in the serum, urine, or involved FLC,presence of 1 or more focus of extramedullary disease (EMD) which meets thefollowing criteria: extramedullary plasmacytoma not contiguous with a bone lesion,at least 1 lesion >=2 centimeter [cm] (at its greatest dimension) diameter on wholebody Positron Emission Tomography and Computed Tomography (PET-CT) Scans (or wholebody magnetic resonance imaging [MRI] approved by sponsor), and not previouslyradiated (Part 2C participants are not required to have measurable disease)

For participants with previously treated AL amyloidosis:

• Initial histopathological diagnosis of amyloidosis

• Participant who is not a candidate for available AL amyloidosis therapy withestablished clinical benefit and should have received at least 3 cycles of 1 priorline of therapy or a total of at least 2 cycles of 2 or more prior lines of therapyfor AL amyloidosis

• Measurable disease at screening defined by at least 1 of the following: seruminvolved free light chain (iFLC) >=50 mg/L or difference between involved anduninvolved free light chains (dFLC) >=50 mg/L, or serum m-protein >= 0.5 g/dL

• One or more organs impacted by systemic AL amyloidosis

• Left ventricular ejection fraction (LVEF) >=45%

Exclusion Criteria:

For participants with relapsed or refractory multiple myeloma:

• Central Nervous System (CNS) involvement or clinical signs of meningeal involvementof multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI)and lumbar cytology are required

• Active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), orprimary light chain amyloidosis

• Received a cumulative dose of corticosteroids equivalent to greater than (>) 140 mgof prednisone within the 14-day period before the start of study treatmentadministration

• Prior antitumor therapy as follows, in the specified time frame prior to the firstdose of study treatment: (proteasome inhibitor [PI] therapy or radiotherapy within 14 days, immunomodulatory drug (IMiD) agent therapy within 7 days, gene-modifiedadoptive cell therapy within 90 days [not applicable for Part 2C participants], orCD3-redirecting therapy within 21 days[not applicable for Part 2B or 2Cparticipants])

• Prior allogeneic transplant within 6 months before the start of study treatmentadministration or autologous transplant within 12 weeks before the start of studytreatment administration

• Live, attenuated vaccine within 4 weeks before the first dose of study treatment

• Non-hematologic toxicity from prior anticancer therapy that has not resolved tobaseline levels or to Grade less than or equal to (<=) 1 (except alopecia, tissuepost-RT fibrosis [any grade] or peripheral neuropathy to Grade <=3)

• The following medical conditions: pulmonary compromise requiring supplemental oxygenuse to maintain adequate oxygenation, human immunodeficiency (HIV) infection, activehepatitis B or C infection, stroke or seizure within 6 months prior to first dose ofstudy treatment, autoimmune disease, serious active viral or bacterial infection,uncontrolled systemic fungal infection, cardiac conditions (myocardial infarction <=6 months prior to enrollment, New York Heart Association stage III or IVcongestive heart failure, et cetera)

• Part 2C: have progressive disease or refractory disease per IMWG after CAR-Tadministration

For participants with previously treated AL amyloidosis:

• CNS involvement or clinical signs of meningeal involvement of AL amyloidosis. Ifeither is suspected, whole brain MRI and lumbar cytology are required

• Any form of non-AL amyloidosis, including but not limited to transthyretin (ATTR)amyloidosis

• Active plasma cell leukemia, Waldenstrom's macroglobulinemia, or POEMS syndrome

• Pulmonary compromise requiring supplemental oxygen use

• Any serious medical conditions such as: active viral, bacterial, fungal infection;active autoimmune disease; HIV infection, active hepatitis B or C infection, strokeor seizure within 6 months prior to first dose of study treatment, significantcardiovascular conditions

• Previous or current diagnosis of symptomatic multiple myeloma

• Macroglossia that impairs swallowing difficulty

• Received a cumulative dose of corticosteroids equivalent to > 140 mg of prednisonewithin the 14-day period before the start of study treatment administration

• Prior antitumor therapy within 21 days prior to the first dose of study treatment (PI therapy or radiotherapy within 14 days, IMiD agent therapy within 7 days,gene-modified adoptive cell therapy within 90 days, or CD3-redirecting therapywithin 21 days)

• Prior allogeneic transplant within 6 months before the start of study treatmentadministration or autologous transplant within 12 weeks before the start of studytreatment administration

• Live, attenuated vaccine within 4 weeks before the first dose of study treatment

• Non-hematologic toxicity from prior anticancer therapy that has not resolved tobaseline levels or to <=1 (except alopecia, tissue post-RT fibrosis [any grade] orperipheral neuropathy to Grade <=3)